People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Xilio Therapeutics, Inc. | — | Biotechnology | Series C | $145.2M | $3.0B | 2021 |
| Normunity Holding Company, LLC | — | Biotechnology | Series C | $83.4M | $273.5M | 2022 |
Rachel Humphrey at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rachel Humphrey on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| DAVID GARDNER | 1 | 20 |
| Michael Ross | 1 | 18 |
| Robert Weisskoff | 1 | 12 |
| Timothy Shannon | 1 | 9 |
| Daniel Lynch | 1 | 7 |
| David Grayzel | 1 | 6 |
| Sakae Asanuma | 1 | 6 |
| Paulina Hill | 1 | 5 |
| Andrew Hack | 1 | 5 |
| Scott Phillips | 1 | 5 |
| Nancy Hong | 1 | 4 |
| Sara Nayeem | 1 | 4 |
| Daniel Curran | 1 | 3 |
| David Parry | 1 | 3 |
| Darlene Deptula-Hicks | 1 | 3 |
| Rene Russo | 1 | 2 |
| Marie-Claire Peakman | 1 | 2 |
| Timothy Clackson | 1 | 2 |
| Peter Dudek | 1 | 2 |
| Paul Clancy | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.